Shopping Cart
- Remove All
Your shopping cart is currently empty
JNJ-10311795
🥰Excellent
Catalog No. T27660Cas No. 518062-14-1
Alias RWJ-355871, RWJ355871, JNJ10311795
JNJ-10311795 (RWJ-355871) is a potent dual inhibitor of neutrophil elastase (Ki = 38 nM) and mast cell chymase (Ki = 2.3 nM) with significant anti-inflammatory activity, useful for studying pneumonia.
JNJ-10311795
🥰Excellent
Purity: 97.43%
Catalog No. T27660Alias RWJ-355871, RWJ355871, JNJ10311795Cas No. 518062-14-1
JNJ-10311795 (RWJ-355871) is a potent dual inhibitor of neutrophil elastase (Ki = 38 nM) and mast cell chymase (Ki = 2.3 nM) with significant anti-inflammatory activity, useful for studying pneumonia.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $293 | In Stock | |
| 5 mg | $722 | In Stock | |
| 10 mg | $987 | In Stock | |
| 25 mg | $1,520 | In Stock | |
| 50 mg | $1,980 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
View MoreBatch Information
Select Batch
Purity:97.43%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | JNJ-10311795 (RWJ-355871) is a potent dual inhibitor of neutrophil elastase (Ki = 38 nM) and mast cell chymase (Ki = 2.3 nM) with significant anti-inflammatory activity, useful for studying pneumonia. |
| Targets&IC50 | Cathepsin G:82 nM |
| In vitro | JNJ-10311795 is a novel effective dual inhibitor of neutrophil cathepsin G (K (i) = 38 nM, IC50 = 82 nM) and mast cell rennet (K (i) = 2.3 nM). [1] |
| In vivo | In a rat model of inflammation, JNJ-10311795 (0.5 mg/kg intravenously) was administered 30 minutes before glycogen therapy, followed by 10 mg/kg/h intravenous infusion for 4.5 hours (total dose = 45.5 mg/kg). The increase in myeloperoxidase was reduced by 50% (neutrophil counts were reduced by 50%). [1] |
| Alias | RWJ-355871, RWJ355871, JNJ10311795 |
| Molecular Weight | 670.69 |
| Formula | C40H35N2O6P |
| Cas No. | 518062-14-1 |
| Smiles | O=C(C=1C=CC=2C=CC=CC2C1)N3CCC(N(C(=O)C4=CC=5C=CC=CC5C=C4C(=O)C(C6=CC=CC=7C=CC=CC76)P(=O)(O)O)C)CC3 |
| Relative Density. | 1.41 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy JNJ-10311795 | purchase JNJ-10311795 | JNJ-10311795 cost | order JNJ-10311795 | JNJ-10311795 chemical structure | JNJ-10311795 in vivo | JNJ-10311795 in vitro | JNJ-10311795 formula | JNJ-10311795 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.